miR-574-3p can suppress target genes, as RAC1 and EP300 both identified its role in stimulating VEGF-mediated angiogenesis, and genistein used to treat prostate cancer can upregulate miRNA-574-3p and thus be used to treat cancer [50]. Here, EP300 is linked to prostate carcinoma.